XML 44 R35.htm IDEA: XBRL DOCUMENT
v3.23.2

Acquisitions (Narrative) (Details) $ / shares in Units, $ in Millions |  | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Dec. 01, 2022 USD ($) | Dec. 31, 2022 USD ($) right $ / shares | Feb. 28, 2022 USD ($) | Sep. 30, 2023 USD ($) $ / shares | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired in-process research and development (Note 3) |  |  |  |  | $ 97.1 | $ 440.4 | $ 202.1 | $ 606.0
Acquired IPR&D |  |  |  |  |  | $ 333.8 |  | $ 333.8
BioMarin Pharmaceutical Inc |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Acquired IPR&D |  |  | $ 110.0 |  |  |  |  |
Akouos Acquisition |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Business acquisition, share price (in dollars per share) | $ / shares |  | $ 12.50 |  |  |  |  |  |
Cash paid, net of cash acquired | $ 327.2 | $ 327.2 |  |  |  |  |  |
Consideration transferred, number of contingent value rights | right |  | 1,000,000 |  |  |  |  |  |
Contingent value right, additional price per share (up to) (in dollars per share) | $ / shares |  | $ 3,000,000.00 |  |  |  |  |  |
Contingent value right, additional price per share, aggregate amount |  | $ 122.0 |  |  |  |  |  |
DICE Therapeutics, Inc | Forecast |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Business acquisition, share price (in dollars per share) | $ / shares |  |  |  | $ 48 |  |  |  |
Payments to acquire businesses |  |  |  | $ 2,400.0 |  |  |  |
Other Pending Acquisitions |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Payments to acquire businesses |  |  |  |  |  |  | $ 1,000.0 |

X
- Definition The amount of expense related to research and development that are acquired directly in a transaction other than a business combination, that do not have an alternative future use and are therefore written off in the period of acquisition + References No definition available. + Details
Name: | lly_AcquiredInProcessResearchAndDevelopment
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business Acquisition, Contingent Value Right, Additional Price Per Share + References No definition available. + Details
Name: | lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare
Namespace Prefix: | lly_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Consideration Transferred, Number Of Contingent Value Rights + References No definition available. + Details
Name: | lly_BusinessCombinationConsiderationTransferredNumberOfContingentValueRights
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments for Asset Acquisitions + References No definition available. + Details
Name: | lly_PaymentsForAssetAcquisitions
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AkouosAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_DICETherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_OtherPendingAcquisitionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |